Oncology medical device company developing tumor-treating fields therapy
Novocure manufactures and commercializes Tumor Treating Fields, an approved cancer therapy, across glioblastoma, non-small cell lung cancer, and mesothelioma indications. The tech stack reveals a pharma-grade operational backbone—SAP S/4HANA + Veeva CRM/Vault for regulated compliance and clinical data—paired with modern cloud infrastructure (AWS, Azure, GCP) and CI/CD tooling (GitLab, Azure DevOps), indicating an organization bridging legacy enterprise systems with engineering-driven data and automation initiatives.
Notable leadership hires: Operations Director, Medical Director
Novocure is a public oncology company headquartered in Baar, Switzerland, with U.S. operations in Portsmouth, New Hampshire and R&D in Haifa, Israel. The company develops and commercializes Tumor Treating Fields therapy, an approved treatment for aggressive cancers including glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma. Active clinical trials are exploring the therapy in glioblastoma, non-small cell lung cancer, and pancreatic cancer. The organization operates across 1,001–5,000 employees and is actively scaling with 95 open roles across support, engineering, healthcare, operations, sales, and data functions across 10+ countries.
Tumor Treating Fields (TTFields), an approved oncology therapy commercialized for glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma, with ongoing trials in pancreatic cancer.
SAP S/4HANA and Veeva (CRM, Vault) for enterprise and clinical data; AWS, Azure, GCP for cloud infrastructure; GitLab CI/CD and Azure DevOps for engineering; Java, Python, JavaScript for development; and testing tools including Selenium, Appium, and Tosca.
Other companies in the same industry, closest in size